Patient baseline demographic and disease characteristics
| Parameter . | Patients with CLL (n = 61) . |
|---|---|
| Age at first serology test, median (IQR), y | 69.4 (59.9-74.6) |
| ≤65, n (%) | 26 (42.6) |
| Males, n (%) | 35 (57.4) |
| Binet stage*, n (%) | |
| A | 27 (81.8) |
| B | 5 (15.2) |
| C | 1 (3.0) |
| IGHV mutational status, n (%) | |
| Mutated | 27 (65.9) |
| Unmutated | 14 (34.1) |
| FISH, n (%) | |
| del(13q) | 13 (33.3) |
| No aberration | 8 (20.5) |
| trisomy12 | 6 (15.4) |
| del(11q) | 11 (28.2) |
| del(17p) | 1 (2.6) |
| β-2-microglobulin | |
| ≤3.5 mg/L | 42 (87.5) |
| >3.5 mg/L | 6 (12.5) |
| Disease/treatment status, n (%) | |
| Treatment-naive | 28 (45.9) |
| On-therapy | 14 (23.0) |
| Previously treated | 19 (31.2) |
| Protocols of currently treated, n (%) | |
| Bruton's tyrosine kinase inhibitors | 9 (64.3) |
| Venetoclax ± anti-CD20 antibody | 5 (35.7) |
| Laboratory parameters, median (IQR) | |
| Absolute lymphocyte count, (×109/L) | 7.6 (2.15-32.5) |
| β-2-microglobulin, mg/L | 2.1 (1.8-3.0) |
| Immunoglobulin G, mg/dL | 969.0 (647.0-1111.0) |
| Immunoglobulin M, mg/dL | 51.5 (28.8-72.5) |
| Immunoglobulin A, mg/dL | 125.0 (66.3-172.3) |
| Parameter . | Patients with CLL (n = 61) . |
|---|---|
| Age at first serology test, median (IQR), y | 69.4 (59.9-74.6) |
| ≤65, n (%) | 26 (42.6) |
| Males, n (%) | 35 (57.4) |
| Binet stage*, n (%) | |
| A | 27 (81.8) |
| B | 5 (15.2) |
| C | 1 (3.0) |
| IGHV mutational status, n (%) | |
| Mutated | 27 (65.9) |
| Unmutated | 14 (34.1) |
| FISH, n (%) | |
| del(13q) | 13 (33.3) |
| No aberration | 8 (20.5) |
| trisomy12 | 6 (15.4) |
| del(11q) | 11 (28.2) |
| del(17p) | 1 (2.6) |
| β-2-microglobulin | |
| ≤3.5 mg/L | 42 (87.5) |
| >3.5 mg/L | 6 (12.5) |
| Disease/treatment status, n (%) | |
| Treatment-naive | 28 (45.9) |
| On-therapy | 14 (23.0) |
| Previously treated | 19 (31.2) |
| Protocols of currently treated, n (%) | |
| Bruton's tyrosine kinase inhibitors | 9 (64.3) |
| Venetoclax ± anti-CD20 antibody | 5 (35.7) |
| Laboratory parameters, median (IQR) | |
| Absolute lymphocyte count, (×109/L) | 7.6 (2.15-32.5) |
| β-2-microglobulin, mg/L | 2.1 (1.8-3.0) |
| Immunoglobulin G, mg/dL | 969.0 (647.0-1111.0) |
| Immunoglobulin M, mg/dL | 51.5 (28.8-72.5) |
| Immunoglobulin A, mg/dL | 125.0 (66.3-172.3) |
Abbreviations: IQR, interquartile range; FISH, fluorescence in situ hybridization; IGHV, immunoglobulin heavy chain.